Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N05AX15
|
| gptkbp:brand |
Reagila
Vraylar |
| gptkbp:CASNumber |
817204-33-4
|
| gptkbp:co-marketedBy |
gptkb:Allergan
gptkb:AbbVie |
| gptkbp:developedBy |
gptkb:Gedeon_Richter
|
| gptkbp:drugClass |
antipsychotic medication
dopamine receptor partial agonist |
| gptkbp:eliminationHalfLife |
1–3 weeks (didesmethyl cariprazine)
2–4 days (cariprazine) |
| gptkbp:hasMolecularFormula |
C21H32Cl2N4O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cariprazine
|
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:mechanismOfAction |
serotonin 5-HT2A receptor antagonist
serotonin 5-HT1A receptor partial agonist dopamine D2 receptor partial agonist dopamine D3 receptor partial agonist |
| gptkbp:metabolism |
liver
desmethyl cariprazine didesmethyl cariprazine |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
11523727
9690539 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
anxiety weight gain restlessness insomnia extrapyramidal symptoms akathisia |
| gptkbp:synonym |
MP-214
RGH-188 Reagila Vraylar |
| gptkbp:UNII |
K83532GS6S
|
| gptkbp:usedFor |
gptkb:bipolar_I_disorder
bipolar disorder schizophrenia manic episodes bipolar depression mixed episodes |
| gptkbp:bfsParent |
gptkb:Richter_Gedeon_Plc
gptkb:Servier_Pharmaceuticals gptkb:Richter_Gedeon |
| gptkbp:bfsLayer |
7
|